Calidi Biotherapeutics, Inc. earnings per share and revenue
On Nov 13, 2025, CLDI reported earnings of -2.21 USD per share (EPS) for Q3 25, missing the estimate of -1.71 USD, resulting in a -28.97% surprise. Revenue reached --, compared to an expected --, with a --% difference. The market reacted with a +0.66% price change (close before vs. close after earnings).
Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
FAQ
What were Calidi Biotherapeutics, Inc.'s earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Calidi Biotherapeutics, Inc. reported EPS of -$2.21, missing estimates by -28.97%, and revenue of --, -- -- expectations.
How did the market react to Calidi Biotherapeutics, Inc.'s Q3 2025 earnings?
The stock price moved up 0.66%, changed from $1.51 before the earnings release to $1.52 the day after.
When is Calidi Biotherapeutics, Inc. expected to report next?
The next earning report is scheduled for --.
What are the forecasts for Calidi Biotherapeutics, Inc.'s next earnings report?
Based on --
analysts, Calidi Biotherapeutics, Inc. is expected to report EPS of -- and revenue of -- for Q-- --.